P
Patricia A. Ganz
Researcher at University of California, Los Angeles
Publications - 745
Citations - 63746
Patricia A. Ganz is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 120, co-authored 701 publications receiving 57204 citations. Previous affiliations of Patricia A. Ganz include University of Massachusetts Medical School & Oklahoma State University Center for Health Sciences.
Papers
More filters
Journal ArticleDOI
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Scott M. Lippman,Eric A. Klein,Eric A. Klein,Phyllis J. Goodman,M. Scott Lucia,Ian M. Thompson,Leslie G. Ford,Howard L. Parnes,Lori M. Minasian,J. Michael Gaziano,Jo Ann Hartline,J. Kellogg Parsons,James D. Bearden,E. David Crawford,Gary E. Goodman,Jaime Claudio,Eric Winquist,Elise D. Cook,Daniel D. Karp,Philip J. Walther,Michael M. Lieber,Alan R. Kristal,Amy K. Darke,Kathryn B. Arnold,Patricia A. Ganz,Regina M. Santella,Demetrius Albanes,Philip R. Taylor,Jeffrey L. Probstfield,T. J. Jagpal,John Crowley,Frank L. Meyskens,Laurence H. Baker,Charles A. Coltman +33 more
TL;DR: Selenium or vitamin E, alone or in combination at the doses and formulations used, did not prevent prostate cancer in this population of relatively healthy men.
Journal ArticleDOI
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G. Vogel,Joseph P. Costantino,D. Lawrence Wickerham,D. Lawrence Wickerham,Walter M. Cronin,Reena S. Cecchini,James N. Atkins,Therese B. Bevers,Louis Fehrenbacher,James L. Wade,Richard G. Margolese,Scott M. Lippman,Carolyn D. Runowicz,Patricia A. Ganz,Steven E. Reis,Leslie G. Ford,V. Craig Jordan,Norman Wolmark +17 more
TL;DR: Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer.
Journal ArticleDOI
Karnofsky performance status revisited: reliability, validity, and guidelines.
TL;DR: Oncologists may train themselves to use the Karnofsky Performance Status in a standard way, which should increase reliability and validity of the KPS and has implications for patients and research studies that use KPS as a stratifying variable.
Journal ArticleDOI
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek,Tara M. Friebel,Christian F. Singer,D. Gareth Evans,Henry T. Lynch,Claudine Isaacs,Judy Garber,Susan L. Neuhausen,Ellen T. Matloff,Rosalind A. Eeles,Gabriella Pichert,Laura Van T'veer,Nadine Tung,Jeffrey N. Weitzel,Fergus J. Couch,Wendy S. Rubinstein,Wendy S. Rubinstein,Patricia A. Ganz,Mary B. Daly,Olufunmilayo I. Olopade,Gail E. Tomlinson,Joellen M. Schildkraut,Joanne L. Blum,Timothy R. Rebbeck +23 more
TL;DR: Among a cohort of women with BRCa1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer, first diagnosis of breastcancer, all-cause mortality, breast cancer-specific mortality, and ovarian cancer- specific mortality.
Journal ArticleDOI
Fatigue in Breast Cancer Survivors: Occurrence, Correlates, and Impact on Quality of Life
Julienne E. Bower,Patricia A. Ganz,Katherine A. Desmond,Julia H. Rowland,Beth E. Meyerowitz,Thomas R. Belin +5 more
TL;DR: Characteristics of fatigued breast cancer survivors are identified that may be helpful in elucidating the mechanisms underlying fatigue in this population, as well as directing intervention efforts.